When was Vesiflo founded?

Vesiflo was founded in 2012 and raised its 1st funding round 3 years after it was founded.

Where is Vesiflo located?

Vesiflo is headquartered in Redmond, United States.

How many employees does Vesiflo have?

As of Jun 30, 2026, the latest employee count at Vesiflo is 3.

Is Vesiflo a funded company?

Vesiflo is a funded company, having raised a total of $5.56M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 25, 2015.

When was the latest funding round of Vesiflo?

Vesiflo's latest funding was a $***** Series A round on Mar 03, 2021, with participation from 0 investor.

Where does Vesiflo rank among its competitors?

Vesiflo ranks 17th amongst 105 active competitors, of which 31 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Australis Scientific, which secured an undisclosed amount in May, 2026.

Who are the top competitors of Vesiflo?

Vesiflo's top competitors include Axonics, Amber Therapeutics and Valencia Technologies. Among them, Australis Scientific secured the most recent funding round in May, 2026.

Vesiflo - 2026 Company Profile, Team, Funding & Competitors

Vesiflo is a series A company based in Redmond (United States), founded in 2012. It operates as a Provider of a non-surgical urinary prosthesis for women with impaired detrusor contractility. Vesiflo has raised $5.56M in funding. The company has 105 active competitors, including 31 funded and 15 that have exited. Its top competitors include companies like Axonics, Amber Therapeutics and Valencia Technologies.

Company Details

Provider of a non-surgical urinary prosthesis for women with impaired detrusor contractility. The lead product is the inFlow Intraurethral Valve-Pump which is a non-surgical urinary prosthesis for women with incomplete bladder emptying due to impaired detrusor contractility. The product is useful in conditions often the consequence of a stroke, Parkinson’s, or diabetes.

Website: vesiflo.com
Social

Key Metrics

Founded Year

2012

Location

Redmond, United States

Stage

Series A

Total Funding

$5.56M in 5 rounds

Latest Funding Round

Series A, Mar 03, 2021, $*****

Investors

Boston Angel Club

Ranked

17^th among 105 active competitors

Employee Count

3 as on Jun 30, 2026

Similar Companies

Fizimed & 39 more

View Vesiflo's full profile

Vesiflo is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Vesiflo, Inc. CIN: 1630392 , United States, Active		$1 - $1M (As on May 19, 2017)	-	-

Vesiflo has raised a total funding of $5.56M over 5 rounds. Its first funding round was on Feb 25, 2015. Vesiflo has 1 institutional investor.

Here is the list of recent funding rounds of Vesiflo:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 03, 2021	7089408	Series A	7471357	5411465	5307866	1361250
May 07, 2019	9804044	Series A	4103425	6861613	2188267	3520483
May 19, 2017	5401396	Series A	9470463	3996415	1588392	8698791

Access funding benchmarks and valuations. Sign up today!

View details of Vesiflo's funding rounds and investors

Vesiflo's employee count trend

Vesiflo has 3 employees as of Jun 26. Here is Vesiflo's employee count trend over the years:

Uncover Vesiflo's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vesiflo include Axonics, Amber Therapeutics and Valencia Technologies. Here is the list of Top 10 competitors of Vesiflo, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Axonics 2013, Irvine (United States), Acquired	Developer of a device to control urinary and bowel movement	$143M	Advent Life Sciences, Edmond de Rothschild ... & 9 others	66/100
2nd	Amber Therapeutics 2021, London (United Kingdom), Series A	Developer of bioelectrical therapies for functional disorders of the peripheral nervous system	$100M	New Enterprise Associates, F-Prime Capital ... & 5 others	59/100
3rd	Valencia Technologies 2011, Santa Clarita (United States), Acquired	Developer of a coin-sized pacemaker-like device for the treatment of hypertension	$56.9M	BMG, Lifeblood Capital & 1 others	59/100
4th	UroMems 2011, Grenoble (France), Series D	Developer of active implantable devices for urological incontinence	$150M	Financiere Arbevel, Supernova Invest & 16 others	59/100
5th	Fizimed 2017, Strasbourg (France), Series A	Manufacturer of device for controlling urinary leakage	$4.35M	Bpifrance, UNIQA Group & 2 others	58/100
6th	Laborie Medical 1967, Mississauga (Canada), Acquired	Provider of products for lower urinary tract dysfunctions in females	-	Investor, Audax Private Equity	57/100
7th	Levee Medical 2021, Durham (United States), Series B	Developer of urological devices for post-prostatectomy	$36.2M	-	57/100
8th	Affluent Medical 2011, Paris (France), Public	Developer of minimally invasive prostheses for structural heart disease, vascular therapy, and urology	$11.7M	Truffle Capital, Hayk Holding & 8 others	55/100
9th	Devicare 2012, Barcelona (Spain), Series A	Developer of home solutions for diagnosis, prognosis, treatment and monitoring of chronic diseases	$7.13M	Advanced MedTech, Ona Capital & 8 others	50/100
10th	Australis Scientific 2021, Fortitude Valley (Australia), Series A	Developing novel medical products that utilise neural modulation technologies	$6M	Rohto Group, ANDHealth	49/100
17th	Vesiflo 2012, Redmond (United States), Series A	Provider of a non-surgical urinary prosthesis for women with impaired detrusor contractility	$5.56M	Boston Angel Club	41/100